3 Stocks to Sell as Ozempic Surges in Popularity
Novo Nordisk's (NYSE: NVO ) Ozempic diabetes treatment, marketed as a weight loss treatment under the Wegovy brand name, has become the latest mega-blockbuster drug. Yet, while you may be thinking about ways to capitalize on its popularity and the rise of other glucagon-like peptide-1 (GLP-1) weight loss treatments, you should also consider the stocks to sell because of this trend.
US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices
The U.S. Senate health panel said on Tuesday it would vote later this month on whether to subpoena Novo Nordisk over the high U.S. prices for weight loss drugs Ozempic and Wegovy compared to those offered in other countries.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
Novo Nordisk has two hugely successful assets in Ozempic and Wegovy. A recent trial also found semaglutide effective for treating chronic kidney disease.
Novo Nordisk's Ozempic sales double to $700 M in China, driven by weight-loss demand
Last year, Novo Nordisk, the Danish pharmaceutical giant, witnessed a significant surge in the sales of its diabetes drug Ozempic in China, doubling its revenue to almost $700 million. This remarkable growth accounts for 5 percent of Ozempic's global sales, underscoring China's pivotal role in the drug's international market.
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
Novo Nordisk is working hard to expand Ozempic's addressable market. The drug is helpful in treating chronic kidney disease, per a new trial.
European stocks open higher as markets anticipate first ECB rate cut since 2019; Novo Nordisk up 3.5%
European stocks opened higher Thursday, with markets anticipating the ECB will cut borrowing costs for the first time since September 2019.
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic
At least 11 generic versions of Novo Nordisk's popular diabetes drug Ozempic are in the final stages of clinical trials in China, as developers seek to profit from an early patent expiry of the therapy's active ingredient semaglutide in China.
Focus: Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed.
Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock
A couple of new scientific studies on Ozempic were just published. Both indicate that the medicine could be useful in treating addiction.
Ozempic Maker Novo Nordisk Stock Up More Than 31% In 2024, But Is It Too Late To Buy Shares?
Novo Nordisk stock traded close to a buy point Friday afternoon as shares bounced from their 21-day line this week.
Fat profits from obesity? Goldman Sachs forecasts weight loss market will hit $130bn by 2030
Goldman Sachs predicts that the global market for obesity treatments will surge to $130 billion by 2030, up from an earlier estimate of $100 billion. This revised forecast reflects the growing demand for anti-obesity medications, particularly those based on GLP-1 receptor agonists, which mimic a hormone that helps regulate appetite and blood sugar levels.
